<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0026">
 <label>26</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Shah</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bloomquist</surname>
    <given-names>E</given-names>
   </name>, 
   <name name-style="western">
    <surname>Tang</surname>
    <given-names>S</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer</article-title>. 
  <source>Clin Cancer Res</source>
  <year>2018</year>;
  <volume>24</volume>:
  <fpage>2999</fpage>–
  <lpage>3004</lpage>.
  <pub-id pub-id-type="pmid">29437768</pub-id>
 </mixed-citation>
</ref>
